TNF and histoplasmosis: On the first estimate, the incidence rate in infliximab users was calculated as 16.7/100,000, and in etanercept users, it was the same.[31] Histoplasmosis was the second most frequent granulomatous disease in people who received a TNF-ɑ inhibitor, second only to tuberculosis, which had an incidence of 129.44 infections per 100,000 infliximab users.